NCT01900041

A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss

Multicenter, Randomised, Open Label, Comparative Clinical Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss (Including AGA Ludwig's Type 1-2)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 74 (actual)
• Sponsor: Merz Pharmaceuticals GmbH · Industry
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

Pantovigar - a high effective product designed primarily for the treatment of diffuse hair loss in women as well as for the treatment of damaged hair, in the combined therapy can be successfully applied in other types of alopecia. The purpose of this study is to evaluate efficacy and tolerability of combination therapy Pantovigar plus 2% minoxidil vs 2% minoxidil. To collect tolerability data for combined treatment Pantovigar plus 2% Minoxidil course therapy.

Conditions

• Female Pattern Hair Loss
• Androgenetic Alopecia (AGA)
• Ludwig Type 1
• Ludwig Type 2

Interventions

Type	Name	Description
DRUG	Pantovigar	1 capsule of Pantovigar for oral intake, given three times a day. Duration of treatment: 6 months.
DRUG	Minoxidil 2% only	1 ML of Minoxidil 2% solution twice a day applied to the scalp. Duration of treatment: 6 months.

Timeline

• Start date: 2012-04-01
• Primary completion: 2013-05-01
• Completion: 2013-07-01
• First posted: 2013-07-16
• Last updated: 2013-12-12

Locations

2 sites across 1 country: Russia